Adaptive Biotechnologies (ADPT) Short Interest Ratio & Short Volume $13.00 +0.37 (+2.93%) Closing price 04:00 PM EasternExtended Trading$13.28 +0.28 (+2.12%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Adaptive Biotechnologies Short Interest DataAdaptive Biotechnologies (ADPT) has a short interest of 9.93 million shares, representing 6.97% of the float (the number of shares available for trading by the public). This marks a 2.48% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.3, indicating that it would take 5.3 days of the average trading volume of 2.04 million shares to cover all short positions.Current Short Interest9,930,000 sharesPrevious Short Interest9,690,000 sharesChange Vs. Previous Month+2.48%Dollar Volume Sold Short$101.68 millionShort Interest Ratio5.3 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares152,274,000 sharesShort Percent of Float6.97%Today's Trading Volume1,947,135 sharesAverage Trading Volume2,039,391 sharesToday's Volume Vs. Average95% Short Selling Adaptive Biotechnologies? Sign up to receive the latest short interest report for Adaptive Biotechnologies and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartADPT Short Interest Over TimeADPT Days to Cover Over TimeADPT Percentage of Float Shorted Over Time Adaptive Biotechnologies Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/20259,930,000 shares $101.68 million +2.5%7.0%5.3 $10.24 7/15/20259,690,000 shares $107.17 million -4.3%N/A4.5 $11.06 6/30/202510,130,000 shares $118.01 million +13.4%7.1%4.5 $11.65 6/15/20258,930,000 shares $92.16 million -7.4%6.3%4.2 $10.32 5/31/20259,640,000 shares $91.77 million +5.9%7.0%4.4 $9.52 5/15/20259,100,000 shares $81.08 million -0.4%6.6%4 $8.91 4/30/20259,140,000 shares $67.27 million -7.6%N/A3.8 $7.36 4/15/20259,890,000 shares $76.55 million -2.3%7.1%5.1 $7.74 3/31/202510,120,000 shares $75.19 million +6.6%7.3%5.2 $7.43 3/15/20259,490,000 shares $69.09 million +9.6%6.9%5.8 $7.28 Get the Latest News and Ratings for ADPT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. 2/28/20258,660,000 shares $71.53 million -1.4%6.3%5.8 $8.26 2/15/20258,780,000 shares $73.14 million +2.9%6.3%6 $8.33 1/31/20258,530,000 shares $66.11 million -1.5%N/A6.1 $7.75 1/15/20258,660,000 shares $62.01 million -5.8%N/A6.5 $7.16 12/31/20249,190,000 shares $55.05 million +1.8%N/A7.7 $5.99 12/15/20249,030,000 shares $56.89 million -5.7%N/A7.3 $6.30 11/30/20249,580,000 shares $56.91 million +16.8%N/A8.1 $5.94 11/15/20248,200,000 shares $41.66 million -8.5%N/A7.2 $5.08 10/31/20248,960,000 shares $43.37 million -5.5%N/A8.5 $4.84 10/15/20249,480,000 shares $47.12 million -4.3%N/A8.2 $4.97 9/30/20249,910,000 shares $50.74 million +2.9%N/A8.1 $5.12 9/15/20249,630,000 shares $44.39 million -0.8%N/A7.6 $4.61 8/31/20249,710,000 shares $45.64 million +0.5%N/A7.4 $4.70 8/15/20249,660,000 shares $47.62 million -11.8%N/A6.6 $4.93 7/31/202410,950,000 shares $49.82 million -8.1%N/A7.3 $4.55 7/15/202411,910,000 shares $48.00 million -1.9%N/A7.9 $4.03 6/30/202412,140,000 shares $43.95 million -7.0%N/A7.4 $3.62 6/15/202413,050,000 shares $40.85 million -2.5%N/A7.6 $3.13 5/31/202413,380,000 shares $46.16 million +1.8%N/A7.8 $3.45 5/15/202413,140,000 shares $51.25 million +9.1%N/A7.9 $3.90 4/30/202412,040,000 shares $31.54 million +20.3%N/A7 $2.62 4/15/202410,010,000 shares $29.13 million +10.0%7.2%6 $2.91 3/31/20249,100,000 shares $29.21 million +7.6%6.6%6.1 $3.21 3/15/20248,460,000 shares $27.41 million -3.5%6.1%5.9 $3.24 2/29/20248,770,000 shares $36.04 million -4.6%N/A5.9 $4.11 2/15/20249,190,000 shares $36.39 million +4.3%N/A6.6 $3.96 1/31/20248,810,000 shares $32.33 million +0.6%N/A5.9 $3.67 1/15/20248,760,000 shares $38.54 million -7.4%N/A5.6 $4.40 12/31/20239,460,000 shares $46.35 million -1.3%N/A6.3 $4.90 12/15/20239,580,000 shares $46.65 million -8.7%N/A6 $4.87Could This Be the End of Retirement Worries? (Ad)Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.Click here to see how to turn your savings into a monthly income machine. 11/30/202310,490,000 shares $45.95 million -6.6%N/A6.8 $4.38 11/15/202311,230,000 shares $48.06 million +4.6%N/A7.3 $4.28 10/31/202310,740,000 shares $47.69 million +8.5%N/A7.7 $4.44 10/15/20239,900,000 shares $42.42 million -6.9%N/A7.4 $4.29 9/30/202310,630,000 shares $57.93 million +7.6%N/A8.1 $5.45 9/15/20239,880,000 shares $59.87 million -5.1%N/A8.4 $6.06 8/31/202310,410,000 shares $70.48 million +3.5%N/A9.1 $6.77 8/15/202310,060,000 shares $63.28 million +5.3%N/A8.7 $6.29 7/31/20239,550,000 shares $80.60 million +6.4%N/A8.8 $8.44 7/15/20238,980,000 shares $64.39 million +12.1%N/A8.9 $7.17 6/30/20238,010,000 shares $53.75 million -0.9%5.8%7.9 $6.71 6/15/20238,080,000 shares $70.05 million +10.4%5.8%8.2 $8.67 5/31/20237,320,000 shares $50.95 million +10.4%5.3%8.2 $6.96 5/15/20236,630,000 shares $43.03 million +8.9%4.8%7.7 $6.49 4/30/20236,090,000 shares $43.48 million +12.2%4.4%6.7 $7.14 4/15/20235,430,000 shares $42.95 million -11.3%3.9%5.9 $7.91 3/31/20236,120,000 shares $54.04 million +14.8%4.4%6.4 $8.83 3/15/20235,330,000 shares $43.81 million +9.5%3.9%5.3 $8.22 2/28/20234,870,000 shares $41.64 million +9.4%3.5%4.9 $8.55 2/15/20234,450,000 shares $44.63 million -6.3%3.2%4.4 $10.03 1/31/20234,750,000 shares $44.03 million -12.4%3.4%4.7 $9.27 1/15/20235,420,000 shares $53.87 million -8.3%3.9%5.2 $9.94 12/30/20225,910,000 shares $45.15 million +25.0%4.2%5.8 $7.64 12/15/20224,730,000 shares $38.45 million -11.1%3.4%4.7 $8.13 11/30/20225,320,000 shares $46.71 million +3.3%3.8%5.2 $8.78 11/15/20225,150,000 shares $46.81 million -13.9%3.7%4.9 $9.09 10/31/20225,980,000 shares $46.52 million -2.3%4.3%5.4 $7.78 10/15/20226,120,000 shares $38.31 million -5.1%4.4%5.4 $6.26 9/30/20226,450,000 shares $45.92 million +3.4%4.6%5.7 $7.12 9/15/20226,240,000 shares $52.67 million -9.4%4.5%4.4 $8.44 8/31/20226,890,000 shares $61.46 million +6.0%4.9%4.4 $8.92 8/15/20226,500,000 shares $82.36 million +1.3%4.7%3.9 $12.67 7/31/20226,420,000 shares $58.81 million -7.6%4.6%3.7 $9.16 7/15/20226,950,000 shares $66.23 million -7.6%5.0%3.9 $9.53 6/30/20227,520,000 shares $60.84 million +2.7%5.4%4.1 $8.09 6/15/20227,320,000 shares $52.34 million +15.5%5.3%4.2 $7.15 5/31/20226,340,000 shares $49.58 million -8.3%4.6%4.4 $7.82 5/15/20226,910,000 shares $56.94 million +32.4%5.0%4.8 $8.24 4/30/20225,220,000 shares $43.07 million -1.9%3.8%3.8 $8.25 4/15/20225,320,000 shares $57.56 million +11.5%3.8%4.1 $10.82 3/31/20224,770,000 shares $66.21 million -12.0%N/A3.8 $13.88 3/15/20225,420,000 shares $58.27 million -0.4%N/A4.5 $10.75 2/28/20225,440,000 shares $78.50 million -5.2%3.9%4.9 $14.43 2/15/20225,740,000 shares $84.32 million +10.0%4.1%5.1 $14.69 1/31/20225,220,000 shares $91.04 million +20.3%3.8%5.3 $17.44 1/15/20224,340,000 shares $83.98 million +14.2%3.1%5 $19.35 12/31/20213,800,000 shares $106.63 million -6.6%2.7%5.1 $28.06 12/15/20214,070,000 shares $111.03 million +8.8%2.9%5.9 $27.28 11/30/20213,740,000 shares $97.58 million -0.8%2.7%5.7 $26.09 11/15/20213,770,000 shares $122.83 million -10.9%2.7%6.3 $32.58Could This Be the End of Retirement Worries? (Ad)Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.Click here to see how to turn your savings into a monthly income machine. 10/29/20214,230,000 shares $141.32 million -0.9%3.0%7.7 $33.41 10/15/20214,270,000 shares $143.05 million -3.2%3.1%8 $33.50 9/30/20214,410,000 shares $149.90 million +4.8%3.2%7.9 $33.99 9/15/20214,210,000 shares $154.13 million +5.3%3.0%7.1 $36.61 8/31/20214,000,000 shares $145.28 million -8.5%2.9%6.8 $36.32 8/13/20214,370,000 shares $138.97 million -8.0%3.2%7.1 $31.80 7/30/20214,750,000 shares $174.14 million +3.9%3.4%6.5 $36.66 7/15/20214,570,000 shares $161.00 million -2.1%3.3%5.8 $35.23 6/30/20214,670,000 shares $190.82 million +11.7%3.4%5.6 $40.86 6/15/20214,180,000 shares $160.43 million -4.1%3.0%4.7 $38.38 5/28/20214,360,000 shares $164.85 million -9.9%3.2%4.4 $37.81 5/14/20214,840,000 shares $162.72 million +1.3%N/A4.1 $33.62 4/30/20214,780,000 shares $204.78 million +9.4%N/A4.5 $42.84 4/15/20214,370,000 shares $186.12 million +1.6%N/A4.3 $42.59 3/31/20214,300,000 shares $161.59 million +12.9%N/A4.1 $37.58 3/15/20213,810,000 shares $158.08 million +10.1%N/A3.8 $41.49 2/26/20213,460,000 shares $191.37 million +14.6%N/A3.6 $55.31 2/12/20213,020,000 shares $194.40 million -4.7%N/A3.8 $64.37 1/29/20213,170,000 shares $181.01 million -26.3%N/A3.8 $57.10 1/15/20214,300,000 shares $282.30 million -6.5%N/A5.2 $65.65 12/31/20204,600,000 shares $273.24 million +7.2%N/A5.8 $59.40 12/15/20204,290,000 shares $245.30 million +10.9%N/A5.1 $57.18 11/30/20203,870,000 shares $181.89 million -46.0%N/A4.5 $47.00 11/15/20207,170,000 shares $352.05 million +49.7%N/A8.3 $49.10 10/30/20204,790,000 shares $248.31 million +18.0%N/A5.7 $51.84 10/15/20204,060,000 shares $210.67 million -22.2%N/A4.6 $51.89 9/30/20205,220,000 shares $253.85 million +26.7%N/A4.9 $48.63 9/15/20204,120,000 shares $189.31 million +35.5%N/A3.9 $45.95 8/31/20203,040,000 shares $126.49 million +27.7%N/A3 $41.61 ADPT Short Interest - Frequently Asked Questions What is Adaptive Biotechnologies' current short interest? Short interest is the volume of Adaptive Biotechnologies shares that have been sold short but have not yet been covered or closed out. As of July 31st, investors have sold 9,930,000 shares of ADPT short. 6.97% of Adaptive Biotechnologies' shares are currently sold short. Learn More on Adaptive Biotechnologies' current short interest. What is a good short interest ratio for Adaptive Biotechnologies? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ADPT shares currently have a short interest ratio of 5.0. Learn More on Adaptive Biotechnologies's short interest ratio. Which institutional investors are shorting Adaptive Biotechnologies? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Adaptive Biotechnologies: Group One Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Adaptive Biotechnologies? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.97% of Adaptive Biotechnologies' floating shares are currently sold short. Is Adaptive Biotechnologies' short interest increasing or decreasing? Adaptive Biotechnologies saw a increase in short interest in July. As of July 31st, there was short interest totaling 9,930,000 shares, an increase of 2.5% from the previous total of 9,690,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Adaptive Biotechnologies' short interest compare to its competitors? 6.97% of Adaptive Biotechnologies' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Adaptive Biotechnologies: Twist Bioscience Corporation (17.83%), 10x Genomics (12.96%), Veracyte, Inc. (7.69%), Grifols, S.A. (1.21%), Legend Biotech Corporation Sponsored ADR (4.26%), Revolution Medicines, Inc. (8.12%), Rhythm Pharmaceuticals, Inc. (7.23%), Avidity Biosciences, Inc. (13.10%), Nuvalent, Inc. (11.99%), Abivax SA Sponsored ADR (2.78%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Adaptive Biotechnologies stock? Short selling ADPT is an investing strategy that aims to generate trading profit from Adaptive Biotechnologies as its price is falling. ADPT shares are trading up $0.37 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Adaptive Biotechnologies? A short squeeze for Adaptive Biotechnologies occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ADPT, which in turn drives the price of the stock up even further. How often is Adaptive Biotechnologies' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ADPT, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies Twist Bioscience Short Interest Data 10x Genomics Short Interest Data Veracyte Short Interest Data Grifols Short Interest Data Legend Biotech Short Interest Data Revolution Medicines Short Interest Data Rhythm Pharmaceuticals Short Interest Data Avidity Biosciences Short Interest Data Nuvalent Short Interest Data Abivax Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ADPT) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access